The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study
Abstract
Background In patients with prostate cancer who are deemed to be at intermediate or high risk of having nodal metastases, invasive diagnostic pelvic lymph-node dissection (PLND) is the gold standard for the detection of nodal disease. However, a new lymph-node-specific MR-contrast agent ferumoxtran-10 can detect metastases in normal-sized nodes (ie, <8 mm in size) by use of MR lymphoangiography (MRL). In this prospective, multicentre cohort study, we aimed to compare the diagnostic accuracy of MRL with up-to-date multidetector CT (MDCT), and test the hypothesis that a negative MRL finding obviates the need for a PLND.Methods We included consecutive patients with prostate cancer who had an intermediate or high risk (risk of >5% according to routinely used nomograms) of having lymph-node metastases. All patients were assessed by MDCT and MRL, and underwent PLND or fine-needle aspiration biopsy. Imaging results were correlated with histopathology. The primary outcomes were sensitivity, specificity, accuracy, NPV, and PPV of MRL and MDCT. This study is registered with ClinicalTrials.gov, number NCT00185029.Findings The study was done in 11 hospitals in the Netherlands between April 8, 2003, and April 19, 2005. 375 consecutive patients were included. 61 of 375 (16%) patients had lymph-node metastases. Sensitivity was 34% (21 of 61; 95% CI 23-48) for MDCT and 82% (50 of 61; 70-90) for MRL (McNemar's test p<0.05). Specificity was 97% (303 of 314; 94-98) for MDCT and 93% (291 of 314; 89-95) for MRL. Positive predictive value (PPV) was 66% (21 of 32; 47-81) for MDCT and 69% (50 of 73; 56-79) for MRL. Negative predictive value (NPV) was 88% (303 of 343; 84-91) for MDCT and 96% (291 of 302; 93-98) for MRL (McNemar's test p<0.05). Of the 61 patients with lymph-node metastases, 50 were detected by MRL, of which 40 (80%) had metastases in normal-sized lymph nodes. The high sensitivity and NPV of MRL imply that in patients with a negative MRL, the chance of positive lymph nodes is less than 11/302 (4%).Interpretation MRL had significantly higher sensitivity and NPV than MDCT for patients with prostate cancer who had intermediate or high risk of having lymph-node metastases. In such patients, after a negative MRL, the post-test probability of having lymph-node metastases is low enough to omit a PLND.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a multicenter clinical trial, the clinical effectiveness of contrast-enhanced MR lymphography was evaluated, producing mixed results, arguably originating from differences in the experience and expertise of the radiologists involved [162].”
From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [162]
Citations
Cites
Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00010 · Cited by 3,219
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., & de Vet, H. C. W. (2003) · BMJ · doi:10.1136/bmj.326.7379.41 · Cited by 3,215
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., van de Kaa, C. H., de la Rosette, J., & Weissleder, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022749 · Cited by 1,971
Self-citationPartin, A. W., Yoo, J. J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I., & Walsh, P. C. (1993) · The Journal of Urology · doi:10.1016/s0022-5347(17)35410-1 · Cited by 1,254
Hövels, A. M., Heesakkers, R. A. M., Adang, E., Jager, G. J., Strum, S. B., Hoogeveen, Y. L., Severens, J. L., & Barentsz, J. O. (2008) · Clinical Radiology · doi:10.1016/j.crad.2007.05.022 · Cited by 956
Self-citationMakarov, D. V., Trock, B. J., Humphreys, E. B., Mangold, L. A., Walsh, P. C., Epstein, J. I., & Partin, A. W. (2007) · Urology · doi:10.1016/j.urology.2007.03.042 · Cited by 474
Risk of prostate carcinoma death in patients with lymph node metastasis
Liang Cheng, C., Zincke, H., Blute, M. L., Bergstralh, E. J., Scherer, B. G., & Bostwick, D. G. (2001) · Cancer · doi:10.1002/1097-0142(20010101)91:1 · Cited by 359
Rockall, A., Sohaib, S. A., Harisinghani, M. G., Babar, S. A., Singh, N., Jeyarajah, A., Oram, D. H., Jacobs, I. J., Shepherd, J. H., & Reznek, R. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.166 · Cited by 338
Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis
Will, O., Purkayastha, S., Chan, C., Athanasiou, T., Darzi, A. W., Gedroyc, W. M. W., & Tekkis, P. P. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70537-4 · Cited by 260
Bellin, M., Roy, C., Kinkel, K., Thoumas, D., Zaïm, S., Vanel, D., Tuchmann, C., Richard, F., Didier Jacqmin, D., Delcourt, A., et al. (1998) · Radiology · doi:10.1148/radiology.207.3.9609907 · Cited by 259
Research works printed but not linked: 1
- El Galley, 1998, Evaluation of staging lymphadenectomy in prostate cancer, Urology, 52, 663, 10.1016/S0090-4295(98)00222-2 · DOI
Cited by
Sorted by citations
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,759
Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications
Dadfar, S. M., Roemhild, K., Drude, N. I., von Stillfried, S., Knüchel, R., Kiessling, F., & Lammers, T. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.005 · Cited by 1,181
Kim, C., Favazza, C. P., & Wang, L. V. (2010) · Chemical Reviews · doi:10.1021/cr900266s · Cited by 807
Maurer, T., Gschwend, J. E., Rauscher, I., Souvatzoglou, M., Haller, B., Weirich, G., Wester, H., Heck, M. M., Kübler, H. R., Beer, A. J., et al. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.12.025 · Cited by 778
Current use of PSMA–PET in prostate cancer management
Maurer, T., Eiber, M. J., Schwaiger, M., & Gschwend, J. E. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.26 · Cited by 613
Metadata
- Authors
- Heesakkers, R. A., Hövels, A. M., Jager, G. J., van den Bosch, H. C., Witjes, J. A., Raat, H. P., Severens, J. L., Adang, E. M., van der Kaa, C. H., Fütterer, J. J., & Barentsz, J.
- Affiliations
- Radboud University Medical Center (NL)
- Jeroen Bosch Ziekenhuis (NL)
- ZorgSaam (NL)
- Maastricht University Medical Centre (NL)
- Corresponding author
- Barentsz, Jelle
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 9
- Issue
- 9
- Pages
- 850-856
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2124586180
- Cited by
- 307
- References
- 40
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 6 · 2023: 9 · 2022: 13 · 2021: 10 · 2020: 16 · 2019: 21 · 2018: 22 · 2017: 19 · 2016: 22 · 2015: 19 · 2014: 21 · 2013: 27 · 2012: 26
- FWCI
- 19.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Radboud Universiteit
- Topics
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- prostate cancer, pelvic lymph node metastasis, MR lymphography, ferumoxtran-10, pelvic lymphadenectomy, multidetector computed tomography, diagnostic accuracy, intermediate- and high-risk prostate cancer, fine-needle aspiration, lymph node staging, negative predictive value, sensitivity and specificity, cost-effectiveness, quality of life
- MeSH terms
- Aged, Aged, 80 and over, Contrast Media, Dextrans, Humans, Iron, Lymph Node Excision, Lymphatic Metastasis, Male, Middle Aged, Oxides, Predictive Value of Tests, Prostatic Neoplasms, Sensitivity and Specificity, Tomography, X-Ray Computed, Echo-Planar Imaging, Ferrosoferric Oxide, Magnetite Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
